Kimbro Melinda Michele
Known title: Chief People OfficerCIK: 0001653953
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
ViaSat sees high call options volume amid sector news. ViaSat is experiencing significant call options volume, suggesting heightened market interest in potential price movement. This activity occurs alongside broader news regarding SpaceX and satellite connectivity, which may be influencing sentiment toward the company. The stock remains within its 52-week range, with technical indicators showing a neutral RSI and confirmed support levels.
Transaction History
| ALHC | ▲ Buy | Grant | 175,439 | $0 | 7/5/2023 | View on chart |
| VSAT | ▲ Buy | Option Exercise | 3,900 | $0 | 12/17/2021 | View on chart |
| VSAT | ▼ Sell | Tax Withholding | 2,054 | $95K | 12/17/2021 | View on chart |
| VSAT | ▲ Buy | Option Exercise | 1,875 | $0 | 11/19/2021 | View on chart |
| VSAT | ▼ Sell | Tax Withholding | 988 | $48K | 11/19/2021 | View on chart |
| VSAT | ▲ Buy | Option Exercise | 4,486 | $0 | 11/17/2021 | View on chart |
| VSAT | ▼ Sell | Tax Withholding | 2,363 | $126K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings
Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings. Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.